Identifying Mechanisms of Resistance to Enzalutamide (MDV3100) Treatment in Men with Castration-Resistant Prostate Cancer

Principal Investigator

Joshi Alumkal

Study Purpose

The purpose of this study is to better understand how cancer treatment of Enzalutamide (MDV3100) may affect prostate cancer cells. The research will involve genetic, molecular, cellular and immunologic experiments using blood and tumor specimens. It is hoped that the information gained from these studies will lead to a greater understanding of castrate-resistant prostate cancer, Enzalutamide resistance and potentially, improvements in cancer treatment.

Medical Condition(s)

Metastatic Prostate Cancer that no longer responds to hormone therapy.

Eligibility Criteria

Prostate cancer that has spread outside the prostate who are eligible to but not yet started treatment with Enzalutamide.

Age Range

18 - 100

Healthy Volunteers Needed


Duration of Participation

You will have study visits when you first start taking Enzalutamide, at week 6 and week 12 after starting Enzalutamide treatment and then every subsequent 12 weeks until your cancer stops responding to Enzalutamide treatment (about 6 months to 3 years). We will continue to check on you by telephone for the rest of your life.

Minors Included



Cancer trials information line: Phone 503-494-1080 or


DOD, Stand Up To Cancer - Prostate Cancer Foundation

Recruitment End


Compensation Provided


Go Back